Antimuscarinic drugs: Review of the cognitive impact when used to treat overactive bladder in elderly patients

Current Urology Reports

Volumn 12, Issue 5, 2011, Pages 351-357

  Pagoria, Dustin ^a   O'Connor, R Corey ^a   Guralnick, Michael L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Anticholinergic; Antimuscarinic; Blood brain barrier; Central nervous system; Cognitive decline; Cognitive effect; Cognitive impairment; Darifenacin; Elderly patients; Fesoterodine; Overactive bladder; Oxybutynin; Solifenacin; Tolterodine; Trospium

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; FESOTERODINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

AGED; ALPHA RHYTHM; ARTICLE; BETA RHYTHM; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DELIRIUM; DEMENTIA; DIZZINESS; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EEG ABNORMALITY; ELECTROENCEPHALOGRAM; FATIGUE; GERIATRIC PATIENT; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; MEMBRANE PERMEABILITY; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NONHUMAN; OVERACTIVE BLADDER; POLYPHARMACY; PSYCHOSIS; RECEPTOR BLOCKING; REM SLEEP; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; THETA RHYTHM; VERTIGO; VISUAL DISORDER; VULNERABLE POPULATION; XEROSTOMIA;

AGED; COGNITION DISORDERS; HUMANS; MUSCARINIC ANTAGONISTS; RECEPTORS, MUSCARINIC; URINARY BLADDER, OVERACTIVE;

EID: 80755190051     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-011-0198-9     Document Type: Article

References (53)

1. WF Stewart JB Van Rooyen GW Cundiff P Abrams AR Herzog R Corey TL Hunt AJ Wein 2003 Prevalence and burden of overactive bladder in the United States World J Urol 20 6 327 36 12811491 1:STN:280:DC%2BD3s3osVWkuw%3D%3D (Pubitemid 44175300)
2. A Tubaro 2004 Defining overactive bladder: epidemiology and burden of disease Urology 64 6 Suppl 1 2 6 15621220 10.1016/j.urology.2004.10.047 (Pubitemid 40038567)
3. S Sigala G Mirabella A Peroni G Pezzotti C Simeone P Spano SC Cunico 2002 Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder Urology 60 4 719 25 12385950 10.1016/S0090-4295(02)01819-8 (Pubitemid 35246475)
4. KE Andersson M Yoshida 2003 Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol 43 1 1 5 12507537 10.1016/S0302-2838(02)00540-7 1:CAS:528:DC%2BD3sXlvFWktrw%3D (Pubitemid 36134308)
5. A Wiedemann PA Schwantes 2007 Antimuscarinic drugs for the treatment of overactive bladder: are they really all the same?-A comparative review of data pertaining to pharmacological and physiological aspects Euro J Ger 9 suppl 1 29 42 This is an excellent review of the mechanisms of action of antimuscarinics at the muscarinic receptors and adverse CNS effects
6. GG Kay LJ Granville 2005 Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly Clin Ther 27 1 127 38 15763613 10.1016/j.clinthera.2005.01.006 1:CAS:528:DC%2BD2MXis1Wltb0%3D quiz 139-140 (Pubitemid 40342583)
7. M Feinberg 1993 The problems of anticholinergic adverse effects in older patients Drugs Aging 3 4 335 48 8369593 10.2165/00002512-199303040-00004 1:STN:280:DyaK3sznvFertQ%3D%3D
8. AA Mangoni SH Jackson 2004 Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications Br J Clin Pharmacol 57 1 6 14 14678335 10.1046/j.1365-2125.2003.02007.x 1:CAS:528:DC%2BD2cXotlOjtA%3D%3D (Pubitemid 38067945)
9. P Abrams KE Andersson 2007 Muscarinic receptor antagonists for overactive bladder BJU Int 100 5 987 1006 17922784 10.1111/j.1464-410X.2007.07205.x 1:CAS:528:DC%2BD2sXhtlGgur7M This is a full review of antimuscarinic drugs with respect to efficacy, tolerability and safety
10. GG Kay MB Abou-Donia WS Messer Jr DG Murphy JW Tsao JG Ouslander 2005 Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients J Am Geriatr Soc 53 12 2195 201 16398909 10.1111/j.1532-5415.2005.00537.x (Pubitemid 43001205)
11. A Wagg C Verdejo U Molander 2010 Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder Int J Clin Pract 64 9 1279 86 20529135 10.1111/j.1742-1241.2010.02449.x 1:STN:280:DC%2BC3cnps1elug%3D%3D This is a review of cognitive side effects of the available antimuscarinics in elderly people
12. NJ Abbott L Ronnback E Hansson 2006 Astrocyte-endothelial interactions at the blood-brain barrier Nat Rev Neurosci 7 1 41 53 16371949 10.1038/nrn1824 1:CAS:528:DC%2BD2MXhtlaktbjP (Pubitemid 41828930)
13. GG Kay U Ebinger 2008 Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin Int J Clin Pract 62 11 1792 800 18699842 10.1111/j.1742-1241.2008.01849.x 1:STN:280:DC%2BD1M%2FntVCgtA%3D%3D The authors explain pathophysiologic mechanisms of cognitive side effects of antimuscarinics and review available literature for each drug in clinical and animal studies
14. M Chancellor T Boone 2011 Anticholinergics for overactive bladder therapy: central nervous system effects CNS Neurosci Ther 00 1 8 This article explains pathophysiologic mechanisms of cognitive side effects of antimuscarinics and reviews the data from various clinical studies on CNS effects of antimuscarinics
15. Callegari E, Malhotra B, Bungay PJ, Webster R, Fenner KS, Kempshall S, Laperle JL, Michel MC, Kay GG. A comprehensive nonclinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011: Accepted Article
16. J Geyer O Gavrilova E Petzinger 2009 The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride Drug Metab Dispos 37 7 1371 4 19389858 10.1124/dmd.109.027144 1:CAS:528:DC%2BD1MXosFenu7s%3D
17. E Tanaka 1998 In vivo age-related changes in hepatic drug-oxidizing capacity in humans J Clin Pharm Ther 23 4 247 55 9867310 10.1046/j.1365-2710. 1998.00164.x 1:CAS:528:DyaK1MXhsVyjsg%3D%3D (Pubitemid 28532449)
18. ML Ancelin S Artero F Portet AM Dupuy J Touchon K Ritchie 2006 Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study BMJ 332 7539 455 9 16452102 10.1136/bmj.38740.439664.DE (Pubitemid 43342043)
19. DG Blazer 2nd CF Federspiel WA Ray W Schaffner 1983 The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations J Gerontol 38 1 31 5 6129272 (Pubitemid 13217827)
20. J Mintzer A Burns 2000 Anticholinergic side-effects of drugs in elderly people J R Soc Med 93 9 457 62 11089480 1:CAS:528:DC%2BD3cXntFOjtLY%3D
21. TM Kessler LM Bachmann C Minder D Lohrer M Umbehr HJ Schunemann AG Kessels 2011 Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach PLoS ONE 6 2 e16718 21373193 10.1371/journal.pone.0016718 1:CAS:528:DC%2BC3MXivVymtLY%3D This is a current meta-analysis of clinical studies specifically focusing on adverse side effects of the available antimuscarinics, showing similar profiles for all except oral oxybutynin at a greater than 10 mg/d dose
22. G Kay T Crook L Rekeda R Lima U Ebinger M Arguinzoniz M Steel 2006 Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects Eur Urol 50 2 317 26 16687205 10.1016/j.eururo.2006. 03.057 1:CAS:528:DC%2BD28XovFWlsLw%3D (Pubitemid 44038078)
23. IR Katz LP Sands W Bilker S DiFilippo A Boyce K D'Angelo 1998 Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride J Am Geriatr Soc 46 1 8 13 9434659 1:CAS:528:DyaK1cXkslWhtw%3D%3D (Pubitemid 28037667)
24. M Gulsun M Pinar U Sabanci 2006 Psychotic disorder induced by oxybutynin: presentation of two cases Clin Drug Investig 26 10 603 6 17163294 10.2165/00044011-200626100-00007 1:CAS:528:DC%2BD28Xht1Wjs7bL (Pubitemid 44411336)
25. A Pietzko W Dimpfel U Schwantes P Topfmeier 1994 Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers Eur J Clin Pharmacol 47 4 337 43 7875185 10.1007/BF00191165 1:CAS:528:DyaK2MXjvFSrsL0%3D (Pubitemid 24363337)
26. A Todorova B Vonderheid-Guth W Dimpfel 2001 Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system J Clin Pharmacol 41 6 636 44 11402632 10.1177/00912700122010528 1:CAS:528:DC%2BD3MXks1Kgsrc%3D (Pubitemid 32493358)
27. K Diefenbach G Arold A Wollny U Schwantes J Haselmann I Roots 2005 Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years BJU Int 95 3 346 9 15679791 10.1111/j.1464-410X.2005.05296.x 1:CAS:528:DC%2BD2MXit1GrsL4%3D (Pubitemid 40283121)
28. DR Staskin SA MacDiarmid 2006 Using anticholinergics to treat overactive bladder: the issue of treatment tolerability Am J Med 119 3 Suppl 1 9 15 16483863 10.1016/j.amjmed.2005.12.011 (Pubitemid 43227968)
29. GSD Kay S MacDiarmid M McIIwain N Dahl 2009 Are the effects of oxybutynin on cognition dependent upon the route of administration - topical or oral? A double-blind placebo controlled study employing sensitive cognitive and psychomotor testing Neurourol Urodyn 28 711 2
30. G Kay K Kardiasmenos T Crook 2006 Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects Neurourol Urodyn 25 615
31. JW Tsao KM Heilman 2003 Transient memory impairment and hallucinations associated with tolterodine use N Engl J Med 349 23 2274 5 14657444 10.1056/NEJM200312043492325 1:CAS:528:DC%2BD3sXps1eitb4%3D (Pubitemid 37485153)
32. S Salvatore M Serati L Cardozo S Uccella P Bolis 2007 Cognitive dysfunction with tolterodine use Am J Obstet Gynecol 197 2 e8 17689620 10.1016/j.ajog.2007.04.051 (Pubitemid 47198192)
33. SG Williams J Staudenmeier 2004 Hallucinations with tolterodine Psychiatr Serv 55 11 1318 9 15534031 10.1176/appi.ps.55.11.1318-a
34. KB Womack KM Heilman 2003 Tolterodine and memory: dry but forgetful Arch Neurol 60 5 771 3 12756144 10.1001/archneur.60.5.771 (Pubitemid 36569899)
35. CR Chapple T Rechberger S Al-Shukri P Meffan K Everaert M Huang A Ridder 2004 Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder BJU Int 93 3 303 10 14764127 10.1111/j.1464-410X.2004.04606.x 1:CAS:528:DC%2BD2cXis1ShsLo%3D (Pubitemid 38253574)
36. A Wagg JJ Wyndaele P Sieber 2006 Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis Am J Geriatr Pharmacother 4 1 14 24 16730617 10.1016/j.amjopharm.2006.03.004 1:CAS:528:DC%2BD28Xht1aktbnK
37. Wesnes KA EC, Tretter RN, Patel H, Bolodeoku J. Solifenacin is not associated with cognitive impairment or sedation in the elderly: the randomized, double-blind SCOPE study. Br Geriatr Soc (Autumn Meeting). 2008; Birmingham, UK: Poster 68
38. J Foote K Glavind G Kralidis JJ Wyndaele 2005 Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist Eur Urol 48 3 471 7 15990219 10.1016/j.eururo.2005.05.009 (Pubitemid 41188407)
39. C Chapple C DuBeau U Ebinger L Rekeda A Viegas 2007 Darifenacin treatment of patients > or = 65 years with overactive bladder: results of a randomized, controlled, 12-week trial Curr Med Res Opin 23 10 2347 58 17706004 10.1185/03007X226294 1:CAS:528:DC%2BD2sXhtlektLzO (Pubitemid 350033436)
40. RB Lipton K Kolodner K Wesnes 2005 Assessment of cognitive function of the elderly population: effects of darifenacin J Urol 173 2 493 8 15643227 10.1097/01.ju.0000148963.21096.5d
41. GG Kay KA Wesnes 2005 Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers BJU Int 96 7 1055 62 16225528 10.1111/j.1464-410X.2005.05745.x 1:CAS:528:DC%2BD2MXht1amtLnF (Pubitemid 41531414)
42. MC Michel 2008 Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome Expert Opin Pharmacother 9 10 1787 96 18570610 10.1517/14656566.9.10.1787 1:CAS:528:DC%2BD1cXnsFeitL8%3D
43. CR Chapple PE Van Kerrebroeck KP Junemann JT Wang M Brodsky 2008 Comparison of fesoterodine and tolterodine in patients with overactive bladder BJU Int 102 9 1128 32 18647298 10.1111/j.1464-410X.2008.07907.x 1:CAS:528:DC%2BD1cXhsFSjs7bF
44. SR Kraus JL Ruiz-Cerda D Martire JT Wang AS Wagg 2010 Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder Urology 76 6 1350 7 20974482 10.1016/j.urology.2010.03.097
45. D Staskin G Kay C Tannenbaum HB Goldman K Bhashi J Ling MG Oefelein 2010 Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder Int J Clin Pract 64 9 1294 300 20561092 10.1111/j.1742-1241.2010.02433.x 1:CAS:528:DC%2BC3cXhtFKrtbnN The SMART trial demonstrated the absence of adverse effects on memory testing in older patients as well as the absence of trospium in these patients' cerebrospinal fluid
46. PK Sand TM Johnson Ii ES Rovner PI Ellsworth MG Oefelein DR Staskin 2010 Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged >/= 75 years) with overactive bladder syndrome BJU Int 107 4 612 20 20707790 10.1111/j.1464-410X.2010.09519.x The authors of this article analyzed pooled data from two phase 3 trials of trospium chloride and demonstrated efficacy and tolerability in elderly patients
47. D Staskin G Kay C Tannenbaum HB Goldman K Bhashi J Ling MG Oefelein 2010 Trospium chloride is undetectable in the older human central nervous system J Am Geriatr Soc 58 8 1618 9 20942892 10.1111/j.1532-5415.2010.02988.x
48. DR Staskin MD Harnett 2004 Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder Curr Urol Rep 5 6 423 6 15541209 10.1007/s11934-004-0064-0
49. PK Sand ES Rovner JH Watanabe MG Oefelein 2011 Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: post hoc analysis of pooled data from two randomized, placebo-controlled trials Drugs Aging 28 2 151 60 21275440 10.2165/11586740-000000000-00000 1:CAS:528:DC%2BC3MXjsFOmurs%3D
50. EL Siegler M Reidenberg 2004 Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia Clin Pharmacol Ther 75 5 484 8 15116061 10.1016/j.clpt.2004.01.015 1:CAS:528:DC%2BD2cXjs1CjtbY%3D (Pubitemid 38534569)
51. KR Edwards JT O'Connor 2002 Risk of delirium with concomitant use of tolterodine and acetyl cholinesterase inhibitors J Am Geriatr Soc 50 6 1165 6 12110086 10.1046/j.1532-5415.2002.50281.x (Pubitemid 34666332)
52. KM Sink J Thomas 3rd H Xu B Craig S Kritchevsky LP Sands 2008 Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes J Am Geriatr Soc 56 5 847 53 18384584 10.1111/j.1532-5415.2008.01681.x The results of this study demonstrated greater functional decline in previously high-functioning nursing home residents taking both an antimuscarinic and cholinesterase inhibitor (Pubitemid 351652414)
53. P Ney RK Pandita DT Newgreen A Breidenbach T Stohr KE Andersson 2008 Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo BJU Int 101 1036 42 18279452 10.1111/j.1464-410X.2007.07358.x 1:CAS:528:DC%2BD1cXmtFOmsLY%3D (Pubitemid 351422555)